Page last updated: 2024-11-13

antofloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

antofloxacin: antibiotic; 8-amino derivative of levofloxacin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24806573
MeSH IDM0513355

Synonyms (14)

Synonym
antofloxacin
56a192vx1q ,
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 8-amino-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3s)-
(s)-antofloxacin
unii-56a192vx1q
119354-43-7
antofloxacin [who-dd]
CS-0181790
Q27261395
(2s)-8-amino-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
HY-123319A
EX-A5689
DTXSID701026060
AKOS040756536

Research Excerpts

Overview

Antofloxacin (AFX) is a novel fluoroquinolone that has been approved in China for the treatment of infections caused by a variety of bacterial species. It has comparable in vitro and animal pharmacological and toxicological properties to levofl Oxacin.

ExcerptReferenceRelevance
"Antofloxacin (AFX) is a novel fluoroquinolone that has been approved in China for the treatment of infections caused by a variety of bacterial species. "( Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X, 2016
)
2.09
"Antofloxacin hydrochloride is a new fluoroquinolone antibiotic with broad-spectrum in vitro activity. "( Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
Xiao, XM; Xiao, YH, 2008
)
2.06
"Antofloxacin hydrochloride is an effective and well-tolerated new fluoroquinolone that demonstrates clinical and bacteriological efficacies similar to levofloxacin for the treatment of AECB and AP."( A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections.
Bai, C; Huang, W; Mei, C; Wang, J; Xiao, Y; Xiu, Q; Xu, N; Zheng, Q, 2010
)
2.13
"Antofloxacin hydrochloride is a newly developed fluoroquinolone antibacterial in China, which has comparable in vitro and animal pharmacological and toxicological properties to levofloxacin and is worthy of further clinical trial. "( Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.
Kang, Z; Li, T; Liu, Y; Lu, Y; Xiao, Y; Zhang, M, 2008
)
2.11

Toxicity

ExcerptReferenceRelevance
" The total incidence of adverse events during the eradication therapy did not significantly differ between the ACLA and LCLA groups (31."( Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP, 2021
)
2.06
" Two groups exhibited similar adverse event rates (AEA 14."( Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.
He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP, 2022
)
1.03

Pharmacokinetics

The purpose of the study was to evaluate the pharmacokinetic characteristics of a single, intravenous dose of antofloxacin hydrochloride in healthy Chinese male volunteers.

ExcerptReferenceRelevance
" The purpose of the present study was to evaluate the pharmacokinetic characteristics of a single oral dose of antofloxacin hydrochloride in Chinese healthy male volunteers."( Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.
Kang, Z; Li, T; Liu, Y; Lu, Y; Xiao, Y; Zhang, M, 2008
)
0.88
" Pharmacokinetic parameters were estimated."( The pharmacokinetics of antofloxacin in renally impaired rats.
Liu, L; Liu, XD; Pang, XY; Wang, GJ; Xie, L; Zhang, DM, 2008
)
0.65
" Using the neutropenic murine thigh infection model, we defined the pharmacodynamic profile and property of antofloxacin hydrochloride against Staphylococcus aureus."( Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
Xiao, XM; Xiao, YH, 2008
)
0.83
"Single-dose pharmacokinetic studies of antofloxacin hydrochloride were carried out in thigh infected mice."( Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
Xiao, XM; Xiao, YH, 2008
)
0.89
"The PK was linear with similar elimination half-life over the dose range studied."( Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
Xiao, XM; Xiao, YH, 2008
)
0.62
"The purpose of the study was to evaluate the pharmacokinetic characteristics of a single, intravenous dose of antofloxacin hydrochloride in healthy Chinese male volunteers."( Pharmacokinetics of antofloxacin hydrochloride, a novel fluoroquinolone, after single-dose intravenous administration in healthy Chinese male volunteers.
Kang, Z; Li, T; Liang, J; Liu, Y; Lu, Y; Wang, J; Xiao, Y; Zhang, M, 2010
)
0.9
" The purpose of the study was to evaluate the pharmacokinetic characteristics of single and multiple oral doses of antofloxacin hydrochloride in Chinese healthy male volunteers."( Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers.
Kang, ZS; Li, TY; Liu, Y; Lü, Y; Xiao, YH; Zhang, M; Zhu, Y, 2011
)
0.81
"The purpose of the study was to evaluate pharmacokinetic characteristics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, during a multiple, intravenous dosing regimen."( Pharmacokinetics of antofloxacin hydrochloride in healthy male subjects after multiple intravenous dose administration.
Kang, Z; Li, T; Liang, J; Liu, Y; Lu, Y; Wang, J; Xiao, Y; Zhang, M, 2011
)
0.92
"To evaluate the pharmacokinetic interactions between theophylline and antofloxacin in vivo and in vitro."( Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans.
Cheng, JL; Fan, HW; Liu, HY; Liu, L; Liu, XD; Pan, X; Xiao, DW; Xie, L; Yang, HW, 2011
)
0.86

Dosage Studied

ExcerptRelevanceReference
" Therapy was initiated at 2 h postinoculation with 5-640 mg/kg per d fractionated for different dosing regimens."( Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
Xiao, XM; Xiao, YH, 2008
)
0.62
" Accumulating elimination rate of antofloxaxin from urine within 120 hours after the last dosing was 60."( Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers.
Kang, ZS; Li, TY; Liu, Y; Lü, Y; Xiao, YH; Zhang, M; Zhu, Y, 2011
)
0.6
"The purpose of the study was to evaluate pharmacokinetic characteristics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, during a multiple, intravenous dosing regimen."( Pharmacokinetics of antofloxacin hydrochloride in healthy male subjects after multiple intravenous dose administration.
Kang, Z; Li, T; Liang, J; Liu, Y; Lu, Y; Wang, J; Xiao, Y; Zhang, M, 2011
)
0.92
"The effect of AT on QT interval prolongation may not have been significant at the dosage of 400 mg."( Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate.
He, YC; Huang, JH; Li, LJ; Li, YF; Liang, LY; Wang, K; Xu, FY; Yang, J; Zheng, QS, 2020
)
0.88
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (32.00)29.6817
2010's13 (52.00)24.3611
2020's4 (16.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.67 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (18.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (50.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]